Alphastrahler Radium-223-Dichlorid
作者： H. Heinzer , F. König , S. Klutmann
DOI: 10.1007/S00120-014-3436-1
关键词:
摘要: Radium-223 dichloride (Ra-223) is an alpha emitter with low toxicity for the treatment of patients castrations-resistant prostate cancer (CRPC) and symptomatic bone metastases showing a 30% reduction in risk death, as compared to placebo. Because favorable physical chemical characteristics, Ra-223 can be handled easily daily practice based on interdisciplinary co-operation between urology nuclear medicine. has been approved under product name Xofigo® by US Food Drug Administration (FDA) European Medicines Agency (EMA).
springer.com
sci-hub.se 参考文章(11)
Øystein Fodstad, Knut Breistøl, Øyvind S. Bruland, Roy H. Larsen, Gjermund Henriksen, Significant Antitumor Effect from Bone-seeking, α-Particle-emitting 223Ra Demonstrated in an Experimental Skeletal Metastases Model Cancer Research. ,vol. 62, pp. 3120- 3125 ,(2002)
J. Ferlay, D.M. Parkin, E. Steliarova-Foucher, Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer. ,vol. 46, pp. 765- 781 ,(2010) , 10.1016/J.EJCA.2009.12.014
Michael Lassmann, Dietmar Nosske, Dosimetry of 223Ra-chloride: dose to normal organs and tissues. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 40, pp. 207- 212 ,(2013) , 10.1007/S00259-012-2265-Y
Gregory R. Mundy, Metastasis to bone: causes, consequences and therapeutic opportunities Nature Reviews Cancer. ,vol. 2, pp. 584- 593 ,(2002) , 10.1038/NRC867
Christopher C. Parker, Sarah Pascoe, Aleš Chodacki, Joe M. O'Sullivan, Josep R. Germá, Charles Gillies O’Bryan-Tear, Trond Haider, Peter Hoskin, A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer European Urology. ,vol. 63, pp. 189- 197 ,(2013) , 10.1016/J.EURURO.2012.09.008
Sten Nilsson, Roy H. Larsen, Sophie D. Fosså, Lise Balteskard, Kari W. Borch, Jan-Erik Westlin, Gro Salberg, Øyvind S. Bruland, First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases Clinical Cancer Research. ,vol. 11, pp. 4451- 4459 ,(2005) , 10.1158/1078-0432.CCR-04-2244
C. Parker, S. Nilsson, D. Heinrich, S.I. Helle, J.M. O'Sullivan, S.D. Fosså, A. Chodacki, P. Wiechno, J. Logue, M. Seke, A. Widmark, D.C. Johannessen, P. Hoskin, D. Bottomley, N.D. James, A. Solberg, I. Syndikus, J. Kliment, S. Wedel, S. Boehmer, M. Dall'Oglio, L. Franzén, R. Coleman, N.J. Vogelzang, C.G. O'Bryan-Tear, K. Staudacher, J. Garcia-Vargas, M. Shan, Ø.S. Bruland, O. Sartor, Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer The New England Journal of Medicine. ,vol. 369, pp. 213- 223 ,(2013) , 10.1056/NEJMOA1213755
Sten Nilsson, Lars Franzén, Christopher Parker, Christopher Tyrrell, René Blom, Jan Tennvall, Bo Lennernäs, Ulf Petersson, Dag C Johannessen, Michael Sokal, Katharine Pigott, Jeffrey Yachnin, Michael Garkavij, Peter Strang, Johan Harmenberg, Bjørg Bolstad, Øyvind S Bruland, Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Lancet Oncology. ,vol. 8, pp. 587- 594 ,(2007) , 10.1016/S1470-2045(07)70147-X
J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, P. Boyle, Estimates of the cancer incidence and mortality in Europe in 2006 Annals of Oncology. ,vol. 18, pp. 581- 592 ,(2006) , 10.1093/ANNONC/MDL498
Chris Parker, Jose E. Garcia-Vargas, C. Gillies O'Bryan-Tear, Fang Fang, Nicholas J. Vogelzang, Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial. Journal of Clinical Oncology. ,vol. 31, pp. 5060- 5060 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.5060